![Mark Demitrack](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Demitrack
Vermogen: 136 $ op 31-12-2025
Profiel
Mark A. Demitrack is currently the Chief Medical Officer at Trevena, Inc. and a Member of the American College of Neuropsychopharmacology.
Previously, he served as the Medical Director-New Antidepressant Team at Lilly Research Laboratories.
From 2003 to 2017, he was the Chief Medical Officer & Vice President at Neuronetics, Inc. He also worked as the Vice President-Clinical Strategy at Roivant Sciences Ltd. from 2017 to 2018 and as the Assistant Vice President-Global Medical Affairs at Wyeth Pharmaceuticals, Inc. Dr. Demitrack completed his undergraduate degree at The Trustees of Columbia University in The City of New York and obtained his doctorate from Robert Wood Johnson Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
TREVENA, INC. 1,32% | 08-10-2024 | 11.363 ( 1,32% ) | 136 $ | 31-12-2025 |
Actieve functies van Mark Demitrack
| Bedrijven | Functie | Begin |
|---|---|---|
| TREVENA, INC. | Hoofd Techniek/Wetenschap/O&O | 21-05-2018 |
American College of Neuropsychopharmacology
 American College of Neuropsychopharmacology Operates as a neuron psychopharmacology school | Corporate Officer/Principal | - |
Eerdere bekende functies van Mark Demitrack
| Bedrijven | Functie | Einde |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 01-05-2018 |
| NEURONETICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2017 |
Wyeth Pharmaceuticals, Inc.
 Wyeth Pharmaceuticals, Inc. Develops, manufactures pharmaceutical products | Corporate Officer/Principal | - |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Corporate Officer/Principal | - |
Opleiding van Mark Demitrack
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Neuronetics, Inc.
 Neuronetics, Inc. Medical SpecialtiesHealth Technology Develops and commercializes non-invasive therapies for psychiatric and neurological disorders | Health Technology |
Roivant Sciences Ltd.
 Roivant Sciences Ltd. Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
 Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly Research Laboratories
Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Commercial Services |
Trevena, Inc.
 Trevena, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and intends to commercialize therapeutics products | Health Technology |
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology Operates as a neuron psychopharmacology school | |
Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. Develops, manufactures pharmaceutical products |
